Glenmark Pharma considers buyback of Singapore FCCBs; stock jumps 3%

INSUBCONTINENT EXCLUSIVE:
consider opportunistic tenders or buybacks of any part of its Singapore listed foreign currency convertible bonds. In a filing to the BSE,
the company said it may make such consideration on its $200 million 2 per cent resettable onward-starting equity-linked securities due June
28, 2022 (issued in 2016), and/or its $200-million 4.5 per cent senior notes (due in 2021) based on market opportunities and conditions from
Committee, based on market opportunities and conditions, will hold meetings during the next one month to consider and approve the terms and